Ignoring a basic pathophysiological mechanism of heart failure progression will not make it go away

Area of Science:

• Cardiology
• Endocrinology
• Thyroid Hormone Research

Background:

• The association between heart failure (HF) and diminished thyroid hormone (TH) function is well-established.
• Current clinical skepticism regarding TH treatment in HF stems from trials using supra-physiological doses of TH analogs, not native THs.
• Challenges in normalizing TH levels in non-cardiac conditions add complexity to TH management in HF.

Discussion:

• Critically evaluates the historical context and limitations of previous clinical trials concerning TH treatment in HF.
• Analyzes the physiological interplay between thyroid hormones and cardiac function.
• Addresses the complexities of thyroid hormone level regulation and therapeutic normalization.

Key Insights:

• Past negative clinical trial outcomes in TH-HF treatment were likely due to inappropriate dosing strategies and the use of TH analogs.
• Understanding the precise role of TH in cardiac function is crucial for developing targeted therapies.
• The persistent clinical interest, evidenced by rising citations, highlights the unresolved questions in TH-HF management.

Outlook:

• Future research should focus on carefully designed trials using appropriate TH formulations and dosing for HF patients.
• Investigating novel therapeutic strategies that modulate thyroid hormone signaling pathways in the heart.
• Clarifying the potential benefits and risks of TH modulation in specific HF subpopulations.